Segall Bryant & Hamill, LLC United Therapeutics Corp Transaction History

Segall Bryant & Hamill, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$212.99 - $276.17 $2,555 - $3,314	12 Added 0.09%	13,632 $3.05 Million
Q4 2022 Feb 14, 2023	BUY	$205.95 - $280.43 $2.81 Million - $3.82 Million	13,620 New	13,620 $3.79 Million
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $3.76 Million - $4.51 Million	18,479 New	18,479 $3.87 Million
Q2 2022 Aug 15, 2022	SELL	$174.81 - $241.14 $697,841 - $962,630	-3,992 Reduced 18.57%	17,504 $4.12 Million
Q1 2022 May 13, 2022	SELL	$166.16 - $213.96 $389,146 - $501,094	-2,342 Reduced 9.82%	21,496 $3.86 Million
Q4 2021 Feb 14, 2022	BUY	$184.32 - $216.08 $105,062 - $123,165	570 Added 2.45%	23,838 $5.15 Million
Q3 2021 Nov 03, 2021	BUY	$179.86 - $214.88 $167,449 - $200,053	931 Added 4.17%	23,268 $4.29 Million
Q2 2021 Aug 12, 2021	BUY	$170.47 - $211.93 $3.81 Million - $4.73 Million	22,337 New	22,337 $4.01 Million

669

42.8M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.7B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.